Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast

BMC Cancer

Volumn 14, Issue 1, 2014, Pages 585-

  Son, Seung Hyun ^a   Kim, Do Hoon ^a   Hong, Chae Moon ^a   Kim, Choon Young ^a   Jeong, Shin Young ^a   Lee, Sang Woo ^a   Lee, Jaetae ^a   Ahn, Byeong Cheol ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

18F FDG PET CT; Breast cancer; Heterogeneity; Intratumoral metabolic heterogeneity; Invasive ductal carcinoma; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROGESTERONE RECEPTOR; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GLYCOLYSIS; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; MAJOR CLINICAL STUDY; METABOLIC HETEROGENEITY; METABOLIC PARAMETERS; OVERALL SURVIVAL; PROTEIN LOCALIZATION; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; TUMOR VOLUME; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; METABOLISM; MORTALITY; MULTIMODAL IMAGING; PAGET NIPPLE DISEASE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SCINTISCANNING; SURVIVAL RATE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84927959720     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-585     Document Type: Article

References (39)

1. Fidler IJ, Hart IR: Biological diversity in metastatic neoplasms: origins and implications. Science 1982, 217:998-1003.
2. Heppner GH: Tumor heterogeneity. Cancer Res 1984, 44:2259-2265.
3. Nicolson GL: Generation of phenotypic diversity and progression in metastatic tumor cells. Cancer Metastasis Rev 1984, 3:25-42.
4. Gillies RJ, Schornack PA, Secomb TW, Raghunand N: Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1999, 1:197-207.
5. Lleonart ME, Martin-Duque P, Sanchez-Prieto R, Moreno A, Ramon y Cajal S: Tumor heterogeneity: morphological, molecular and clinical implications. Histol Histopathol 2000, 15:881-898.
6. Dick JE: Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807.
7. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T: Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992, 33:1972-1980.
8. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N: Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 1994, 35:104-112.
9. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL: Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 1995, 36:1854-1861.
10. Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M, Takei T, Tamaki N: Biologic correlates of intratumoral heterogeneity in 18FFDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 2005, 46:675-682.
11. Xu HN, Zheng G, Tchou J, Nioka S, Li LZ: Characterizing the metabolic heterogeneity in human breast cancer xenografts by 3D high resolution fluorescence imaging. Springerplus 2013, 2:73.
12. Derlon JM, Chapon F, Noel MH, Khouri S, Benali K, Petit-Taboue MC, Houtteville JP, Chajari MH, Bouvard G: Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 2000, 27:778-787.
13. Henriksson E, Kjellen E, Wahlberg P, Ohlsson T, Wennerberg J, Brun E: 2-Deoxy-2-[18F] fluoro-D-glucose uptake and correlation to intratumoral heterogeneity. Anticancer Res 2007, 27:2155-2159.
14. 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol 2008, 87:55-58.
15. 18F-FDG uptake as a predictor of patient outcome. J Nucl Med 2008, 49:1973-1979.
16. Kidd EA, Grigsby PW: Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res 2008, 14:5236-5241.
17. 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 2011, 52:369-378.
18. Newbold KL, Partridge M, Cook G, Sharma B, Rhys-Evans P, Harrington KJ, Nutting CM: Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer. Acta Oncol 2008, 47:1229-1236.
19. Schinagl DA, Kaanders JH, Oyen WJ: From anatomical to biological target volumes: the role of PET in radiation treatment planning. Cancer Imaging 2006, 6:S107-S116.
20. Schutze C, Bergmann R, Yaromina A, Hessel F, Kotzerke J, Steinbach J, Baumann M, Beuthien-Baumann B: Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol 2007, 83:311-315.
21. Tanderup K, Olsen DR, Grau C: Dose painting: art or science? Radiother Oncol 2006, 79:245-248.
22. American Cancer Society: Breast Cancer Facts & Figures 2011-2012. Atlanta: American Cancer Society, Inc; 2012.
23. 18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 2008, 38:250-258.
24. 18F]-D-glucose. Cancer 1998, 82:2227-2234.
25. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S: Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol 2004, 130:273-278.
26. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual. 7th edition. New York: Springer; 2010.
27. Tavassoli FA, Devilee P: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
28. Miller TR, Grigsby PW: Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 2002, 53:353-359.
29. Soret M, Bacharach SL, Buvat I: Partial-volume effect in PET tumor imaging. J Nucl Med 2007, 48:932-945.
30. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
31. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002, 8:S62-S67.
32. Heppner GH, Miller BE: Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev 1983, 2:5-23.
33. Heppner GH, Miller BE: Therapeutic implications of tumor heterogeneity. Semin Oncol 1989, 16:91-105.
34. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ: Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006, 38:468-473.
35. Hoey T: Drug resistance, epigenetics, and tumor cell heterogeneity. Sci Transl Med 2010, 2:28ps19.
36. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J Nucl Med 2013, 54:333-340.
37. Cooper C, Liu GY, Niu YL, Santos S, Murphy LC, Watson PH: Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clin Cancer Res 2004, 10:8720-8727.
38. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB: Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006, 12:4562-4568.
39. Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB: Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 2009, 27:227-234.